Vaccine biotechnology represents the application of advanced molecular and cellular techniques to develop, produce, and optimize vaccines. Traditional vaccine production often involved using weakened or inactivated forms of pathogens. In contrast, biotechnology allows for the creation of vaccines using specific genetic material, proteins, or subunits associated with the target pathogen. Recombinant DNA technology enables the insertion of genes encoding pathogenic proteins into host cells, such as yeast or bacteria, to produce large quantities of antigenic proteins for vaccine development. This approach enhances precision and safety in vaccine design. The advent of mRNA vaccine technology, exemplified by COVID-19 vaccines, represents a groundbreaking application of biotechnology. mRNA vaccines provide a platform for rapid response to emerging infectious diseases by delivering genetic instructions to cells, prompting them to produce viral proteins and induce an immune response. Biotechnological advancements also enable the development of subunit vaccines, virus-like particles, and vector-based vaccines. These approaches enhance the specificity, safety, and scalability of vaccine production, contributing to the development of novel vaccines against a wide range of infectious diseases. Ongoing research in vaccine biotechnology continues to revolutionize the field, offering innovative solutions for global health challenges.
Submit your abstract Today
